BGM Group Ltd. income statement
In fiscal 2025, BGM Group Ltd. reported revenue of $37.9m, up 51.1% on the year before, operating income of −$12.6m (a -33.2% margin) and net income of −$19.9m, or −$0.18 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2018Sept 2018 | 2019Sept 2019 | 2020Sept 2020 | 2021Sept 2021 | 2022Sept 2022 | 2023Sept 2023 | 2024Sept 2024 | 2025Sept 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50 | 46 | 50 | 57 | 65 | 46 | 25 | 38 |
| Cost of revenue | 42 | 36 | 42 | 51 | 59 | 45 | 21 | 32 |
| Gross profit | 8 | 10 | 8 | 6 | 6 | 2 | 4 | 6 |
| Research and development | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 2 | 4 | 3 | 3 | 4 | 4 | 3 | 18 |
| Operating income | 6 | 6 | 5 | 2 | 2 | −3 | −1 | −13 |
| Interest expense | 0 | 0 | 0 | 0 | — | — | — | — |
| Net interest income | — | — | −0 | −0 | 0 | 0 | — | — |
| Income before tax | 6 | 7 | 6 | 3 | 2 | −8 | −2 | −20 |
| Income tax | 1 | 1 | 1 | 0 | 0 | 0 | −1 | 0 |
| Net income | 5 | 6 | 5 | 3 | 1 | −8 | −1 | −20 |
| Diluted EPS | $0.06 | $0.06 | $0.06 | $0.03 | $0.01 | −$0.07 | −$0.01 | −$0.18 |
| Diluted shares (average) | 90m | 90m | 90m | 102m | 108m | 108m | 108m | 113m |
| EBITDA | 7 | 7 | 6 | 4 | 3 | −1 | 1 | −11 |
Compare with peers
- IM Cannabis Corp. income statement
- Cumberland Pharmaceuticals Inc income statement
- Sunshine Biopharma Inc. income statement
- Scilex Holding Co income statement
- Biofrontera Inc. income statement
Head to head: BGM vs IMCCBGM vs CPIXBGM vs SBFM
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies